HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (24) Citing Articles via Google Scholar Google Scholar Articles by Humphreys, M. H. Search for Related Content PubMed PubMed Citation Articles by Humphreys, M. H.

INVITED REVIEW

-MSH, sodium metabolism, and salt-sensitive hypertension

Division of Nephrology, San Francisco General Hospital; and Department of Medicine, University of California San Francisco, San Francisco, California 94143

	ABSTRACT

TOP ABSTRACT POMC METABOLISM AND PROCESSING THE MELANOCORTINS AND THEIR... CARDIOVASCULAR ACTIONS OF... {gamma}-MSH AND NATRIURESIS {gamma}-MSH AND THE... {gamma}-MSH AND SODIUM... {gamma}-MSH AND SALT-SENSITIVE... THE {gamma}-MSH SYSTEM IN... GRANTS REFERENCES

 
-, -, and -melanocyte stimulating hormones (MSHs) are melanotropin peptides that are derived from the ACTH/-endorphin prohormone proopiomelanocortin (POMC). They have been highly conserved through evolutionary development, although their functions in mammals have remained obscure. The identification in the last decade of a family of five membrane-spanning melanocortin receptors (MC-Rs), for which the melanotropins are the natural ligands, has permitted the characterization of a number of important actions of these peptides, although the physiological function(s) of -MSH have remained elusive. Much evidence indicates that -MSH stimulates sympathetic outflow and raises blood pressure through a central mechanism. However, this review focuses on newer cardiovascular and renal actions of the peptide, acting in most cases through the MC3-R. In rodents, a high-sodium diet (HSD) increases the pituitary abundance of POMC mRNA and of -MSH content and results in a doubling of plasma -MSH concentration. The peptide is natriuretic and acts through renal MC3-Rs, which are also upregulated by the HSD. Thus the system appears designed to participate in the integrated response to dietary sodium excess. Genetic or pharmacologic induction of -MSH deficiency results in marked salt-sensitive hypertension that is corrected by the administration of the peptide, probably through a central site of action. Deletion of the MC3-R also produces salt-sensitive hypertension, which, however, is not corrected by infusion of the hormone. These observations in aggregate suggest the operation of a hormonal system important in blood pressure control and in the regulation of sodium excretion. The relationship of these two actions to each other and the significance of this system in humans are important questions for future research.

peptide hormone; pituitary; proopiomelanocortin; melanotropin; central nervous system; neurointermediate lobe

	POMC METABOLISM AND PROCESSING

TOP ABSTRACT POMC METABOLISM AND PROCESSING THE MELANOCORTINS AND THEIR... CARDIOVASCULAR ACTIONS OF... {gamma}-MSH AND NATRIURESIS {gamma}-MSH AND THE... {gamma}-MSH AND SODIUM... {gamma}-MSH AND SALT-SENSITIVE... THE {gamma}-MSH SYSTEM IN... GRANTS REFERENCES

 
POMC is best known as the prohormone of ACTH and -endorphin. It is heavily expressed in corticotrophs of the anterior lobe of the pituitary and in melanotrophs of the intermediate lobe. However, it is also expressed in other parts of the central nervous system (CNS), notably the arcuate nucleus of the hypothalamus and the nucleus of the solitary tract and in extracranial tissues, including the skin, testis, thyroid, placenta, pancreas, gastrointestinal tract, kidney, and liver (21, 111). It is the product of a single gene composed of three exons separated by two introns, a structure similar among all mammalian species. Current understanding holds that circulating POMC-derived peptides are secreted from the pituitary, whereas peptides in extrapituitary tissues function in an autocrine or paracrine manner.

Processing of POMC into its component peptides is driven by two prohormone convertases, PC1 and PC2. These are subtilisin-like endoproteases that cleave polypeptides at sites of dibasic amino acid pairs (Lys-Lys, Lys-Arg, Arg-Arg, Arg-Lys), and all the POMC-derived peptides are flanked by such pairs. PC1 is expressed predominately in anterior lobe corticotrophs and to only a low extent in intermediate lobe (20, 132); it cleaves POMC into the larger peptides ACTH, -lipotropin, and the large NH₂-terminal fragment. PC2 is more prominent in melanotrophs of the intermediate lobe but is also expressed at low levels in anterior lobe corticotrophs; its action gives rise to the smaller peptides -endorphin and -, -, and -MSH (132). Other enzymes are involved in COOH-terminal amidation and NH₂-terminal acetylation of some of these peptides to complete processing.

Regulation of POMC synthesis and processing occurs through markedly different mechanisms in anterior and intermediate lobes. In anterior lobe corticotrophs, the major stimulus for POMC synthesis is CRF from the hypothalamus (4, 111). This peptide induces a rapid increase in POMC gene transcription and its mRNA. Glucocorticoids exert a negative feedback control on POMC gene expression by inhibiting POMC gene expression directly and also reduce the expression of PC1 and PC2 (20). In the intact animal, synthesis of POMC by corticotrophs is the resultant of CRF-mediated stimulation balanced by glucocorticoid inhibition. A number of other regulatory factors including vasopressin, catecholamines, serotonin, and angiotensin II have also been shown to regulate POMC expression (4, 111).

Regulation in the neurointermediate lobe (NIL) is mediated primarily by the neurotransmitter dopamine acting through the dopamine D₂ receptor. In NIL, this receptor is negatively coupled to adenylate cyclase; activation of the receptor inhibits POMC gene expression and secretion of derived peptides, whereas antagonism of the receptor upregulates POMC expression (4, 111). Abundance of PC1 and PC2 mRNA and protein move in parallel with POMC mRNA in response to dopaminergic stimulation or antagonism (20, 94). These processing enzymes act in a coordinate manner to mediate specific endoproteolytic cleavages of POMC at dibasic amino acid pairs in a strict temporal order, with PC1 acting initially and PC2 later to generate the smaller peptides secreted from the NIL (132, 133). PC2 requires the coexpression of the neuroendocrine protein 7B2 for normal activation (6) (see below).

	THE MELANOCORTINS AND THEIR RECEPTORS

TOP ABSTRACT POMC METABOLISM AND PROCESSING THE MELANOCORTINS AND THEIR... CARDIOVASCULAR ACTIONS OF... {gamma}-MSH AND NATRIURESIS {gamma}-MSH AND THE... {gamma}-MSH AND SODIUM... {gamma}-MSH AND SALT-SENSITIVE... THE {gamma}-MSH SYSTEM IN... GRANTS REFERENCES

 
- and -MSH were identified in the 1950s because of their action to induce pigment dispersion in skin melanocytes of amphibia and reptiles. In 1979, Nakanishi and colleagues (83) deduced the amino acid sequence of the whole POMC molecule from its complementary DNA. They identified in the NH₂-terminal fragment a region bearing homology with - and -MSH in a core heptapeptide. Because this region was separated by dibasic amino acid cleavage sites, they predicted that the intervening peptide would be a secretory product of POMC and termed it -MSH because of this homology to - and -MSH. They surmised that it too would possess the pigmentary capabilities of its two relatives. This has proven not to be the case, but much work has revealed that -MSH possesses important cardiovascular actions not shared by its cousins. Three species of -MSH have been recognized (Fig. 1). ₁-MSH contains 11 amino acids and is identical to ₂-MSH without the COOH-terminal glycine and with COOH-terminal amidation. ₃-MSH is a 25-amino acid peptide formed by cleavage at the next dibasic amino acid cleavage site. The functional significance of these different forms of -MSH is not completely clear but has bearing on their cardiovascular actions, as will be described shortly.

View larger version (24K): [in this window] [in a new window]   Fig. 1. A: overview of the proopiomelanocortin (POMC) molecule showing the dibasic amino acid sites of processing into the hormones derived from it. B: amino acid sequences of melanocyte stimulating hormone (MSH) peptides. -, -, and -MSH share a core heptapeptide sequence. Three species of -MSH have been recognized as described in the text. [Borrowed with permission of the American Heart Association (54a).]

As discussed earlier, - and -MSH are processed chiefly in the intermediate lobe and secreted into the circulation. The pigmentary function of -MSH in mammals is minor, yet the highly conserved nature of POMC fueled a search for other functions of these peptides, and it has become clear that they are involved in a wide variety of important actions. This work was facilitated by the cloning of a family of five receptors with which the peptides interact (Table 1). These receptors are members of the superfamily of seven-transmembrane-spanning receptors and share considerable amino acid homology among themselves. They are positively coupled to adenylate cyclase, and their activation results in an increase in cellular cAMP (80, 107). However, other signaling pathways have been identified, including activation of inositol trisphosphate with mobilization of intracellular calcium (59, 79), an influx of extracellular calcium (58), and the MAP kinase pathway (33). The MC1-R is the receptor mediating the classical effects of -MSH on melanin dispersion; it is expressed by cutaneous melanocytes but is also found on monocytes and other immunomodulatory cells and has been proposed to mediate the anti-inflammatory actions of -MSH (41, 107). Loss-of-function mutations of MC1-R in humans are relatively common and are associated with red hair color (110). The MC2-R is expressed in the zona fasciculata and zona reticularis of the adrenal cortex and is responsible for the stimulation of glucocorticoid synthesis by ACTH. It binds ACTH with high affinity but does not interact appreciably with the melanocortins (108), although an earlier report (43) suggested a possible role of -MSH in some forms of idiopathic hyperaldosteronism (see below). Aldosterone synthesis takes place in the zonal glomerulosa and is transiently regulated by ACTH. Mutations in MC2-R result in autosomal recessive familial isolated glucocorticoid deficiency (19, 116, 125).

The MC3-R is expressed in brain, chiefly in hypothalamus, cortex, and thalamus, as well as in peripheral tissues including gut and placenta (22, 42, 104). In the hypothalamus, it is found in the arcuate nucleus, an important site of extrapituitary POMC synthesis and processing. It has also been detected in human and rat kidney (15, 85), which is relevant to the natriuretic actions of the melanocortins to be discussed below. Of the five melanocortin receptors cloned to date, -MSH has affinity in the nanomolar range only for MC3-R, leading to the conclusion that it is the natural ligand for this receptor. Deletion of the MC3-R gene by homologous recombination in the mouse leads to a condition of altered energy metabolism wherein body weight remains normal but there is an increase in adipose tissue and a decrease in locomotor activity (10); as will also be discussed below, these mice develop marked salt-sensitive hypertension.

The MC4-R is heavily expressed in almost all brain regions and in the spinal cord (41, 107). It has highest affinity for -and -MSH but rather low affinity for -MSH, and the current viewpoint is that -MSH is its natural ligand. Targeted disruption of the MC4-R gene results in a phenotype of hyperphagia, obesity, and insulin resistance (56). The MC5-R is expressed at low levels in numerous tissues including skeletal muscle, brain, adrenal gland, kidney, lung, testis, and uterus (41, 107). It is also detected in exocrine glands like the Harderian, preputial, sebaceous, and lacrimal glands and is found as well in prostate and pancreas. Targeted deletion of this receptor gene results in a widespread impairment of exocrine gland function manifested by defects in water expulsion and thermoregulation (13).

Table 1 also lists the relative affinities of the major POMC-derived melanotropin peptides for the five receptors. These data are summaries of results of in vitro binding experiments and measurements of cAMP generation in cellular systems and may not reflect activity in vivo. As will be pointed out later in this review, ₂-MSH, acting through MC3-R, selectively corrects the salt-sensitive hypertension observed in -MSH-deficient rodents; equimolar infusions of -MSH are without effect, even though the two peptides are reported to have similar affinities for MC3-R in vitro.

	CARDIOVASCULAR ACTIONS OF -MSH

TOP ABSTRACT POMC METABOLISM AND PROCESSING THE MELANOCORTINS AND THEIR... CARDIOVASCULAR ACTIONS OF... {gamma}-MSH AND NATRIURESIS {gamma}-MSH AND THE... {gamma}-MSH AND SODIUM... {gamma}-MSH AND SALT-SENSITIVE... THE {gamma}-MSH SYSTEM IN... GRANTS REFERENCES

 
-MSH and ACTH-(1-24) have been shown to exert resuscitative effects in models of hemorrhagic and septic shock (reviewed in Refs. 41, 107, 127). Some of these actions occur through a central site of action, whereas others appear to result from inhibition of production of cytokines like TNF-. These anti-inflammatory actions inhibit acute renal and hepatic injury in rodent models (16, 17, 18); -MSH and structurally related peptides are not effective (127). On the other hand, -MSH-like peptides have been recognized to possess a variety of cardiovascular actions not shared by - and -MSH. Injections of -MSH intravenously or into a carotid artery result in a transient pressor and cardioaccelerator response that is due to central activation of sympathetic outflow. This may involve a vasopressinergic pathway, because it is blunted in Brattleboro rats lacking vasopressin (45), although not all observations are consistent with this (119). It likely also involves a neural circuit in the anteroventral region of the third ventricle, because lesions of this region reduced the pressor response to intravenous -MSH (11). This part of the hypothalamus lies outside the blood-brain barrier and so can respond to intravenously delivered peptide. -MSH administered directly into the cerebroventricular system (icv) also raises blood pressure but over a different time course of 10-15 min as opposed to a few seconds (115). In general, -MSH has no effect on blood pressure or heart rate when given intravenously (23, 101, 121). However, it elevates blood pressure and heart rate when given intracerebroventricularly (29, 47, 72). This effect results from stimulation of sympathetic outflow and is mediated via MC4-Rs (74, 75). In contrast, microinjection of -MSH into the dorsovagal complex of the medulla or the nucleus of the solitary tract lowers blood pressure and heart rate (65, 95), also likely mediated via MC4-R (65, 95). This action may help to explain the observation that acute intracerebroventricular administration of -MSH raises blood pressure, whereas chronic administration lowers it (47). -MSH itself produced bradycardia and lowered blood pressure when injected directly into the nucleus of the solitary tract in contrast to its effects when given intravenously or intracerebroventricularly (24, 65). These observations indicate that the circuitry mediating the various cardiovascular actions of these peptides is complex; whereas the usual effect of -MSH peptides is to elevate blood pressure and heart rate, a vasodepressor effect can be manifest when they are injected directly into specific brain regions or when sympathetic outflow is depressed as under certain conditions of anesthesia (23, 44).

Structure-function studies have identified some features of MSH peptides that account for their cardiovascular activities. The sequence Arg-Phe at positions 10 and 11 of ₁- and ₂-MSH is necessary for the hypertensive effect of these peptides when administered intravenously, because analogs like -MSH that lack them have no activity (Fig. 1). They must be at or near the COOH terminus, because ₃-MSH possesses this sequence but also has a long COOH-terminal extension and is inactive relative to the shorter forms when injected intravenously; however, it was equipotent to ₂-MSH in raising mean arterial pressure (MAP) when given into the cerebral ventricle (101), raising the possibility that its greater size in some way restricts its access to active sites in the central nervous system. Asp at position 9 confers selectivity for MC3-R relative to MC4-R (91). NH₂-terminal shortening produces peptides that maintain cardiovascular activity, with -MSH-(6-12) being if anything more potent than ₂-MSH (89, 120, 121, 122). These observations, and others, raise important questions about the melanocortin receptor(s) mediating these activities. As discussed above, the cardiovascular actions of -MSH appear to be mediated by MC4-R. -MSH has affinity in the concentration range at which it circulates only for MC3-R, and it would be reasonable to consider this receptor to mediate the pressor and tachycardic actions of this group of peptides. However, Li and colleagues (65) found that the hypertensive effect of intravenous ₂-MSH was not blocked by intracarotid injection of the MC3-R and MC4-R antagonist SHU9005, and others observed that the ability of peptide fragments to bind to and activate the various receptors correlated very poorly with their effects on blood pressure and heart rate; indeed, -MSH-(6-12) failed to activate in vitro the MC3-R, MC4-R, or MC5-R yet possessed potent activity in vivo (120, 121, 122). Such observations as these have led to the suspicion that the cardiovascular actions of -MSH and related peptides are mediated by an as yet undetected melanocortin receptor and/or a different class of receptor (65, 89, 123). Speculation has centered on the FMRFamide-gated sodium channel as a candidate receptor. FMRFamide (Phe-Met-Arg-Phe-NH₂) was originally isolated from ganglia of the clam Macrocallista nimbosa (98), and a related peptide, neuropeptide FF (Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH₂), later identified in bovine brain (Ref. 57; reviewed in Ref. 105). These and related peptides are pressor and cardioaccelerator when injected systemically through central activation of the sympathetic nervous system, with a time course identical to that of ₁-MSH (81, 115). Thiemermann and associates (115) studied a number of related peptides and observed that the dipeptide Arg-Phe was the most potent pressor. Arg-Phe-NH₂ is the NH₂-terminal sequence of ₁-MSH; as discussed earlier, these two amino acids are necessary for the pressor actions of ₁-MSH and ₂-MSH. In 1995, Lingueglia and colleagues (71) reported the cloning of an amiloride-sensitive FMRFamide peptide-gated sodium channel from snail nervous tissue, for which FMRFamide and possibly related sympathoexcitatory peptides like ₁- and ₂-MSH could be the natural ligands. Subsequent work has suggested that activation of this system may be involved in the development of salt-sensitive hypertension (51, 90). These observations are relevant to the finding of salt-sensitive hypertension in -MSH-deficient rodents presented below. Although much more work needs to be done, the possibility exists that this amiloride-sensitive sodium channel could be the receptor activated by -MSH and related peptides to increase sympathetic outflow, raising blood pressure and heart rate. The availability of MC3-R-deficient mice (10) should allow definitive conclusions about the role of this receptor in the cardiovascular actions of MSH peptides; in a preliminary study, we observed that the cardiovascular responses to injections of -MSH are the same in wild-type and MC3-R knockout mice (86), a finding that argues against any role of MC3-R in these responses.

	-MSH AND NATRIURESIS

TOP ABSTRACT POMC METABOLISM AND PROCESSING THE MELANOCORTINS AND THEIR... CARDIOVASCULAR ACTIONS OF... {gamma}-MSH AND NATRIURESIS {gamma}-MSH AND THE... {gamma}-MSH AND SODIUM... {gamma}-MSH AND SALT-SENSITIVE... THE {gamma}-MSH SYSTEM IN... GRANTS REFERENCES

 
Early studies by Orias and McCann (92), and subsequently by Hradec and Horky (49), demonstrated that - and -MSH were natriuretic when injected intraperitoneally into the rat and hamster. In 1984, Lymangrover and associates (73) showed that ₂-MSH also is natriuretic when injected as a bolus intravenously in doses from 0.64 to 64 pmol; doses higher than 64 pmol lost natriuretic activity. These groups of investigators concluded that the natriuretic effect of MSH peptides was likely a direct one on the kidney, although the systemic route of administration of the peptides did not allow a firm conclusion on this point. In 1987, Lin and colleagues (67) reported that ₂-MSH was natriuretic when infused directly into the renal artery at a rate that caused no change in sodium excretion from the contralateral kidney. This clearly indicated an intrarenal mechanism for the natriuresis; because no change in glomerular filtration rate occurred, the data were interpreted to indicate that the natriuresis resulted from inhibition of tubular sodium reabsorption (14, 67).

The mechanism of -MSH natriuresis has not been fully elucidated. Both mRNA and protein for MC3-R, MC4-R, and MC5-R have been identified in rat renal cortex and medulla (85), although their exact cellular localization has not been determined. Studies showed that the MC3-R and MC4-R antagonists SHU9005 and SHU9119 (50) infused intrarenally blocked the natriuresis induced by -MSH, supporting a receptor-mediated mechanism of action (14). Excretion rates of both cGMP (U_cGMPV) and cAMP (U_cAMPV) increased in proportion to the increase in sodium excretion after intravenous infusion of -MSH, and U_cGMPV also rose after intrarenal -MSH infusion (14). Excretion rates of cyclic nucleotides are often used as indexes of hormonal action in the kidneys; as discussed earlier, melanocortin receptors are positively coupled to adenylate cyclase, and the increase in U_cGMPV was therefore surprising. An increase in plasma atrial natriuretic peptide (ANP) concentration was observed after intravenous infusion of -MSH, so the possibility of an indirect effect of the peptide, acting through ANP to cause natriuresis, was raised (14). However, neutralization of secreted ANP by treatment with an anti-ANP antiserum did not alter the natriuresis caused by intravenous infusion of -MSH, and the authors concluded that the increase in plasma ANP resulting from -MSH infusion was not involved in the renal actions of this peptide (14). This same study also indicated that the renal nerves may be involved in the natriuretic effect of -MSH. Acute renal denervation blocked the natriuresis caused by intrarenal infusion of the peptide, whereas denervation did not alter the natriuresis resulting from intrarenal ANP infusion (14). The nature of this interaction between the renal nerves and -MSH-mediated natriuresis remains to be defined.

	-MSH AND THE POSTNEPHRECTOMY NATRIURESIS

TOP ABSTRACT POMC METABOLISM AND PROCESSING THE MELANOCORTINS AND THEIR... CARDIOVASCULAR ACTIONS OF... {gamma}-MSH AND NATRIURESIS {gamma}-MSH AND THE... {gamma}-MSH AND SODIUM... {gamma}-MSH AND SALT-SENSITIVE... THE {gamma}-MSH SYSTEM IN... GRANTS REFERENCES

 
Interest in the possible role of -MSH as a physiological regulator of sodium metabolism arose from studies of the natriuresis that occurs after acute unilateral nephrectomy (AUN). The postnephrectomy natriuresis was first clearly described by Peters (97) and has been confirmed in numerous subsequent reports. The natriuresis from the remaining kidney occurs within minutes of AUN (26, 27, 100) and takes place without an increase in glomerular filtration rate (GFR), indicating that it results from a decrease in tubular sodium reabsorption (69, 70, 97, 103). Although a transient increase in MAP is observed after AUN (5, 26, 87; see below), there is no overall increase in blood pressure that could account for the natriuresis. Because there is no discernible change in the volume or composition of the blood after AUN, a neurohumoral mechanism was suggested to mediate the postnephrectomy natriuresis. Such a mechanism could be considered to represent the efferent limb of a reflex arc activated by AUN, the other components of which include afferent inputs and central integrative pathways.

Several components involved in this reflex natriuresis after AUN have been identified and are summarized in Fig. 2. The reflex is initiated by the abrupt rise in arterial pressure that occurs immediately after clamping of the renal artery (5, 26, 87; Fig. 2, #1). This in turn is the result of the hydrodynamic consequence of the removal of one organ vascular resistance circuit (the kidney) in parallel with the multiple other regional vascular resistance networks (the other kidney, brain, heart, skeletal muscle, splanchnic circulation, etc.) that contribute to total peripheral resistance. In a parallel circuit, removal of one component must inevitably lead to an increase in overall resistance. Because cardiac output initially is unchanged and maintains constant flow, the result of the increased resistance is an increase in arterial pressure sensed by high-pressure baroreceptors in the carotid sinus. This rise in blood pressure proved to be the signal initiating the reflex: prevention of this hemodynamic consequence of AUN by opening a peripheral arteriovenous (AV) fistula at the time of AUN also prevented the postnephrectomy natriuresis (53), and both the hemodynamic changes and the excretory response resemble those seen on closure of a chronic AV fistula (52). Subsequent reflex effects reduce cardiac output and restore blood pressure back to control (52, 53, 54). Additional experiments established the importance of the carotid sinus baroreceptors (Fig. 2, #2): maneuvers that interfered with normal carotid sinus function or that prevented transmission of the increased pressure signal to the baroreceptors also prevented the postnephrectomy natriuresis (5). CNS involvement was more clearly established in the natriuretic response to AUN by experiments demonstrating that ventriculocisternal perfusion with pharmacologic agents blocked the natriuresis at doses that had no effect when given systemically (68; Fig. 2, #3). A role of the pituitary emerged from the finding that the postnephrectomy natriuresis did not occur in hypophysectomized animals (70; Fig. 2, #4). Finally, pituitary POMC became implicated when the plasma concentration of immunoreactive material from the midregion of the NH₂-terminal fragment of POMC, termed NTF_32-49, was observed to increase after AUN in a manner that was closely correlated with the increase in U_NaV (70). Further evidence of a pituitary source for the secretion of this immunoreactivity came from studies in which a lesion of the arcuate nucleus of the hypothalamus was produced by neonatal administration of monosodium glutamate (69). The arcuate nucleus is an important neuroendocrine control station regulating pituitary function; rats treated in this manner exhibit a number of endocrine, metabolic, and behavioral disturbances attributed to altered pituitary function (84). Rats with this lesion failed to increase either U_NaV or plasma NTF_32-49 concentration after AUN. This lack of response was associated with a reduction in NTF-like material in the pituitary of these rats (69).

View larger version (24K): [in this window] [in a new window]   Fig. 2. Schematic model to depict the reflex activated by acute unilateral nephrectomy that results in natriuresis by the remaining kidney. See -MSH AND THE POSTNEPHRECTOMY NATRIURESIS for details. [Modified from Ref. 52, with permission of the publisher.]

We speculated that -MSH could be the component of the NH₂-terminal region of POMC that was associated with the postnephrectomy natriuresis, and we obtained evidence consistent with this possibility (67). AUN led to natriuresis that was accompanied by an increase in plasma -MSH immunoreactivity. This increase correlated with the increase in NTF_32-49 (100) and with the increase in U_NaV (67); as discussed above, the peptide itself was natriuretic when infused either intravenously or directly into one renal artery. Pretreatment with rabbit anti--MSH antiserum blocked the natriuretic response to AUN (63). These observations therefore suggested that -MSH acted as a classic circulating hormone after AUN (Fig. 2, #5): its concentration in plasma (presumably reflecting increased secretion) rose after AUN but not after sham nephrectomy; it possessed natriuretic potency when infused intravenously or directly in one renal artery; and the presence of an antiserum, which likely bound and rendered inactive any freshly released peptide, prevented the postnephrectomy natriuresis. The characteristics of the antiserum used in these studies led to the conclusion that ₂-MSH, as opposed to ₁- or ₃-MSH, mediates the natriuretic response (55, 67, 100). Of note, no change in the plasma concentration of another POMC-derived peptide, ACTH, occurred after AUN, suggesting a selective effect of this maneuver on secretion of ₂-MSH. Moreover, no change in plasma ANP concentration was observed, indicating that activation of this potent natriuretic pathway was not responsible for the postnephrectomy natriuresis (100). Further support for mediation of the natriuresis after AUN by -MSH came from experiments in which the melanocortin receptor antagonists SHU9119 and SHU9005 were infused into the renal artery of the remaining kidney before carrying out AUN. These compounds have high potency and selectivity for the MC3-R and MC4-R while retaining full agonist activity at MC1-R and MC5-R (50). Intrarenal infusion of either compound prevented the postnephrectomy natriuresis despite equivalent elevations of plasma -MSH concentration (87), providing additional evidence for a receptor-mediated mechanism as being responsible for the natriuresis.

Mention was made earlier that renal denervation prevented the natriuretic response to infusion of -MSH. Similarly, renal denervation also prevented the postnephrectomy natriuresis (55, 103) but in a complex manner. Renal innervation appeared necessary for the nephrectomy to stimulate -MSH release into the circulation, a requirement that was attributed to afferent renal nerves (103; Fig. 2, #6).

	-MSH AND SODIUM METABOLISM

TOP ABSTRACT POMC METABOLISM AND PROCESSING THE MELANOCORTINS AND THEIR... CARDIOVASCULAR ACTIONS OF... {gamma}-MSH AND NATRIURESIS {gamma}-MSH AND THE... {gamma}-MSH AND SODIUM... {gamma}-MSH AND SALT-SENSITIVE... THE {gamma}-MSH SYSTEM IN... GRANTS REFERENCES

 
The identification of a role of -MSH in the reflex natriuresis initiated by AUN suggested the possibility that this humoral system could be involved in a more general way in sodium metabolism. Indeed, the components of this reflex arc (baroreceptor inputs, hypothalamic integration, hypothalamic-pituitary axis) mediate other circumstances of body fluid homeostasis and circulatory control. Duchen (28) demonstrated an increase in the number of secretory granules in NIL but not anterior lobe (AL) of rats drinking hypertonic saline, and Howe and Thody (48) extended this observation by measuring an increase in NIL MSH content by bioassay in rats drinking 2% saline for 10-15 days. Elkabes and Loh (32) measured plasma -MSH concentration and pituitary POMC mRNA and synthetic rate in mice drinking either tap water or 2% saline solution. They observed that plasma -MSH concentration, reflecting secretion from the NIL, fell after 2 days of the high sodium intake but then returned to baseline from 4 to 12 days after starting the high intake. POMC mRNA abundance in the NIL was reduced after 2 days of saline ingestion and then returned to baseline; in contrast, it was elevated in the AL 2 days after introduction of the high sodium intake, returning to baseline at later time points (32). The authors interpreted their results to indicate that sodium ingestion exerts divergent effects on POMC metabolism in the different pituitary lobes and that salt loading may interact with other regulators of pituitary function such as stress to account for their observations (32). Subsequently, Hao and Rabkin (46) showed that a high-sodium diet (8% NaCl) increased POMC mRNA in pituitaries of Dahl salt-resistant rats; they did not measure plasma peptide concentrations. To evaluate this issue more, we studied rats on a high-sodium diet (HSD; 8% NaCl) vs. a low-sodium diet (LSD; 0.07%) to determine if changes in plasma -MSH concentration occurred. Animals ingesting the HSD had a significantly greater (P < 0.001) concentration of -MSH in plasma compared with rats on the LSD; the -MSH level was twice the value in animals on the LSD (77). As expected, the ANP level was also increased. No difference in plasma ACTH concentration occurred, and no correlation could be demonstrated between the concentrations of ACTH and -MSH. These results thus provide an example where peptides from the NH₂-terminal region of POMC may be processed and secreted differently from ACTH, in contrast to the conclusion drawn by Elkabes and Loh (32) that they reflect a nonspecific response driven by ACTH release resulting from the stress imposed by the HSD.

These findings suggested that the HSD has a preferential effect on pituitary POMC processing into -MSH and secretion of the peptide into the circulation. We quantitated POMC mRNA abundance in whole pituitaries of these rats and observed a progressive increase in message abundance after 1, 2, and 3 wk of ingesting the HSD (77); in situ hybridization studies indicated that the increase in mRNA abundance was largely confined to the NIL and was accompanied by a large increase in -MSH immunoreactivity in this lobe but not the AL (77; Fig. 3). A subsequent study confirmed the effect of the HSD to increase plasma -MSH concentration as well as the POMC signal in NIL and in addition demonstrated that the mRNAs of the processing enzymes PC1 and PC2, as well as PC2 protein abundance, were also increased in NIL but not AL after 3 wk of the HSD (12). In aggregate, these observations all point to a coordinated upregulation of the POMC--MSH system in NIL in response to the HSD: the HSD initiates a signal that reaches the NIL to increase the mRNA abundance of POMC and the enzymes required for its processing into -MSH. Secretion of the peptide into the circulation increases its plasma concentration and results in natriuresis. This scheme suggests that the system is one component of the integrated response to states of sodium excess and thereby contributes to the maintenance of normal sodium balance.

View larger version (37K): [in this window] [in a new window]   Fig. 3. A: in situ hybridization photomicrographs of pituitaries from rats fed a high-sodium diet (HSD; left) or a low-sodium diet (LSD; right) for 1 wk using a 32P-labeled POMC cRNA probe. Signal intensity is much greater on the high-sodium diet, and the signal is confined to the neurointermediate lobe. B: quantification of -MSH immunoreactivity in anterior and neurointermediate lobes of rat pituitaries after ingestion of HSD or LSD for 1 wk. Immunoreactivity was low in anterior lobe and was not affected by dietary sodium intake. Immunoreactivity was much higher in intermediate lobe and was doubled by ingestion of the HSD. [Modified from Ref. 71 with permission of the American Heart Association.]

To be natriuretic, the peptide must interact with receptors within the kidney. The absence of any change in GFR during -MSH natriuresis argued for a site of action on the renal epithelium where receptors must be located on the surface of renal tubular cells. Mentioned earlier were the reports of renal expression of MC3-R, the melanocortin receptor subtype with which -MSH interacts (15, 85). In the rat kidney, mRNA and protein for MC3-R, MC4-R, and MC5-R have been detected in both cortex and medulla in roughly equal abundance during ingestion of a LSD. During an HSD, both the mRNA and protein abundance of MC3-R more than doubled in medulla but not cortex, whereas expression of the other receptors did not change (85). It thus seems that the HSD not only activates synthesis and secretion of -MSH from the NIL but also upregulates the expression of its receptors in the kidney, thereby amplifying the potency of its natriuretic action. This is in contrast to the ANP system, which is also activated by the HSD: plasma ANP concentration increases, but there is no change in the renal expression of the ANP receptor natriuretic peptide receptor (NPR)-A (37, 113). This dual action of the HSD to increase not only plasma -MSH concentration but also its receptor MC3-R in the kidney argues that this system is an important component of the integrated response to states of sodium surfeit.

	-MSH AND SALT-SENSITIVE HYPERTENSION

TOP ABSTRACT POMC METABOLISM AND PROCESSING THE MELANOCORTINS AND THEIR... CARDIOVASCULAR ACTIONS OF... {gamma}-MSH AND NATRIURESIS {gamma}-MSH AND THE... {gamma}-MSH AND SODIUM... {gamma}-MSH AND SALT-SENSITIVE... THE {gamma}-MSH SYSTEM IN... GRANTS REFERENCES

 
The possibility of involvement of altered POMC metabolism in the pathogenesis of hypertension has been considered. Gaida and colleagues (40) found that -endorphin immunoreactivity was increased in NIL of stroke-prone spontaneously hypertensive rats (SHR) and was not affected by antihypertensive treatment with clonidine, whereas Felder and Garland (35) observed that synthesis of POMC by hypertensive rat pituitary NIL was blunted compared with normotensive rats. Pharmacologic treatment of hypertensive rats with a variety of agents restored blood pressure to normal and also normalized POMC synthesis, leading the authors to conclude that the blunted synthesis while hypertensive was a consequence rather than a cause of the hypertension (35). These studies did not quantitate POMC mRNA, nor were the pituitary changes related to circulating concentrations of peptides derived from POMC. In contrast to these observations of altered POMC metabolism in NIL of hypertensive rats, Braas and associates (8) found reduced levels of POMC peptides and POMC mRNA in anterior lobes of hypertensive rats. In none of these studies was the temporal relationship of blood pressure changes to POMC metabolism examined or the consequence of alterations in sodium intake on these variables studied. Hao and Rabkin (46) reported still different results after measuring POMC mRNA in pituitaries of Dahl salt-resistant and salt-sensitive rats. They observed an increase in POMC mRNA abundance in resistant rats ingesting an HSD but not in salt-sensitive rats. They could not determine if this difference between salt resistant and salt sensitive was causally related to the hypertension of sensitive rats or a result of it, nor did they relate it to changes in circulating concentration of any POMC-derived peptides. Their study followed the earlier work of Rapp and Dahl (102), who showed decreased protein synthesis and -MSH content in NIL in response to sodium loading in salt-sensitive compared with salt-resistant rats. We also observed in preliminary studies that Dahl salt-sensitive rats failed to increase pituitary POMC mRNA when ingesting the HSD and also did not increase plasma -MSH concentration (76). These last observations raise the possibility that impaired POMC metabolism may contribute to salt-sensitive hypertension.

The renal and cardiovascular effects of ₁- and ₂-MSH have also been studied in SHR and the normotensive control Wistar-Kyoto (WKY) rats (114). Both peptides caused dose-dependent increases in MAP and heart rate in conscious intact rats that were not observed in rats that had been pithed. These authors also presented data indicating that intravenous infusion of nonpressor doses of ₂-MSH led to equivalent natriuresis in both SHR and WKY, suggesting that the natriuretic component of the peptide's actions was preserved in this form of genetically hypertensive rat. On the other hand, a preliminary study indicated that intrarenal infusion of ₂-MSH in untreated SHR did not exert a natriuretic action; treatment with the angiotensin-converting inhibitor captopril, added to the drinking water for 7-10 days, lowered MAP from 161 to 120 mmHg and restored natriuretic responsiveness to intrarenal infusion of ₂-MSH (131). The basis for these divergent observations on the renal action of -MSH in SHR has not been determined.

More recent studies in rodents with -MSH deficiency or resistance identify the importance of the -MSH system in sodium metabolism. Mention was made earlier of the importance of PC2 in the processing of POMC into its secretory product -MSH. Mice with targeted deletion of the PC2 gene were first reported in 1997 by Steiner's group (38); these mice exhibit a modest impairment in growth and have lower blood glucose concentration than their wild-type littermates but are otherwise phenotypically normal. They demonstrate defective processing of a number of peptide hormones in addition to POMC (3, 7, 39). PC2 knockout mice were compared with wild-type mice while ingesting either the LSD or the HSD for 1 wk; MAP was measured under ketamine-xylazine anesthesia, and plasma -MSH concentration was assayed. In wild-type mice fed the HSD, plasma peptide concentration was more than double the value observed in mice fed the LSD, whereas MAP was not significantly different (88) (Fig. 4); these results parallel those described above in normal rats. However, in PC2 knockout mice a different picture emerged. Plasma -MSH concentration on the LSD was only 15% of the value seen in wild-type mice and was not any higher in knockout mice on the HSD. MAP in these mice on the LSD was marginally elevated compared with wild-type mice (104 vs. 83 mmHg) but was dramatically increased in knockout mice ingesting the HSD (158 mmHg; Fig. 4). Thus absence of functional PC2 led to -MSH deficiency and was accompanied by a marked degree of salt-sensitive hypertension (88). To test the role of the -MSH deficiency in the hypertension, we infused the peptide at a low rate and found that it rapidly lowered MAP to normal values, whereas -MSH was without effect. This blood pressure-lowering effect of -MSH resulted from a central site of action, because a low dose of the peptide, which was without effect when administered intravenously, promptly reduced MAP in hypertensive knockout mice when given into the cerebroventricular system (88).

View larger version (13K): [in this window] [in a new window]   Fig. 4. Mean arterial pressure (MAP; A) and plasma -MSH concentration (B) in mice with targeted disruption of the proconvertase 2 gene (PC2-/-) vs. wild type mice (PC2+/+) after ingesting a LSD or HSD for 1 wk. In wild-type mice, the HSD did not influence MAP but plasma -MSH concentration more than doubled. In PC2-/- mice, plasma -MSH concentration was reduced on the LSD and did not increase during ingestion of the HSD. MAP was markedly elevated on the HSD, demonstrating that these mice had salt-sensitive hypertension. *Significantly greater than other values, P < 0.001. [Reproduced from Ref. 82 with permission of the American Society of Clinical Investigation.]

PC2 requires interaction with the neuroendocrine protein 7B2 for its maturation and development of full enzymatic activity. 7B2 is a small, acidic protein that is localized to neuroendocrine tissues and that binds to PC2 early in the secretory pathway (6). Although one might expect that reduction of PC2 activity by disruption of 7B2 would lead to a similar phenotype as observed in PC2 knockout mice (38), 7B2 null mice are markedly different (126). They show absence of PC2 enzymatic activity and impaired processing of proglucagon to glucagon but, in contrast to PC2 knockout mice, have markedly elevated plasma levels of ACTH and corticosterone and adrenal cortical expansion; they die before 9 wk of age of severe Cushing's syndrome caused by excessive NIL secretion of ACTH (126). Adrenalectomy with steroid hormone replacement rescues the lethal phenotype of these mice, which also exhibit a defect in dopaminergic suppression of NIL ACTH secretion (62). Blood pressure was not reported in these studies, and it is not known if secretion of -MSH from the intermediate lobe was also impaired in 7B2 null mice. The basis for the phenotypic differences between PC2 knockout and 7B2 null mice is not clear, but these differences indicate that interruption of normal prohormone processing by PC2 can lead to pleiotropic effects.

The findings described above in PC2 knockout mice argue that -MSH deficiency results in salt-sensitive hypertension and document therefore the important role of this peptide in sodium metabolism. We sought to determine if -MSH resistance also resulted in a hypertensive phenotype by measuring MAP on the LSD vs. HSD in mice with targeted disruption of the MC3-R or MC4-R. Mc3r-/- mice exhibit a unique metabolic syndrome characterized by an increase in adipose tissue mass without obesity and with reduced energy expenditure (10), whereas Mc4r-/- mice are phenotypically obese with increased adipose tissue, hyperphagia, and insulin resistance (56). Mc3r-/- mice had a plasma -MSH concentration on the LSD that was more than double the value observed in wild-type controls, and the value increased even more in knockout mice ingesting the HSD. This suggested that these knockouts have a hormone-resistant state. MAP reflected the results in PC2-/- mice: it was somewhat higher in knockout mice on the LSD than in wild-type mice but became markedly hypertensive in Mc3r-/- mice that had been ingesting the HSD for 1 wk (88). In contrast to PC2-/- mice, infusion of -MSH had no effect on MAP in these Mc3r-/- mice, indicating that the restoration of MAP to normal by -MSH administration to hypertensive PC2-/- mice required integrity of this receptor. Mc4r-/- mice were normotensive on both the LSD and HSD (88).

In aggregate, these experiments paint a picture of a humoral system, the disruption of which, either by impairment of normal secretion or by blunting of its signaling through its receptor, results in salt-sensitive hypertension. Such a finding indicates the importance of this system in normal sodium metabolism. The mechanism(s) by which interruption of -MSH signaling causes hypertension is not yet clear. Plasma renin activity and plasma aldosterone concentration were equivalently suppressed during ingestion of the HSD in PC2-/- mice, arguing that these important determinants of MAP were not involved. Intravenously infused -MSH increased U_NaV in hypertensive PC2-/- mice as MAP was falling to normal levels, but the rapidity of the blood pressure-lowering effect of the peptide makes a reduction in plasma volume from the natriuresis seem unlikely. Moreover, cerebroventricular administration of the peptide led to even more rapid correction of MAP in doses that had no effect given intravenously, so that natriuresis could not be the mechanism by which MAP was lowered. However, the natriuretic property of the peptide could certainly interact with its blood pressure-lowering action to participate in the overall regulation of the circulation and body fluid volumes. The central site of action of the peptide given to -MSH-deficient mice suggests that it may possibly reduce central sympathetic outflow, an interesting hypothesis in view of the literature cited earlier in this review documenting the effect of -MSH, at much higher doses, to stimulate sympathetic outflow. Obviously, much further work will be required to characterize fully the mechanism(s) underlying salt-sensitive hypertension that occurs as a result of impaired -MSH signaling.

The pleiotropic consequences of PC2 deficiency, as described above, raise the concern that systems in addition to -MSH could contribute to the hypertension that these animals display. We consequently used a pharmacologic approach in an effort to interfere with NIL processing of POMC without perturbing other systems dependent on PC2. As discussed earlier, the major pathway regulating NIL function involves dopaminergic suppression. We treated male rats with the dopamine agonist bromocriptine (5 mg/kg ip by daily injection) or the dopamine receptor antagonist haloperidol (5 mg/kg ip each day) for 1 wk while they were ingesting either the LSD or the HSD and compared the results with those in vehicle-treated rats. Vehicle-treated rats on the HSD showed an elevation in plasma -MSH concentration and NIL -MSH content compared with rats ingesting the LSD (78) as we had seen earlier (77); MAP did not differ in the two groups. Haloperidol-treated rats had elevated plasma and NIL -MSH levels on the LSD, and these did not increase further on the HSD. MAP again was no different in the two groups. Bromocriptine treatment produced opposite results. Neither plasma -MSH concentration nor NIL -MSH content was elevated in bromocriptine-treated rats on the HSD compared with LSD values, and, interestingly, MAP was significantly higher in the HSD animals (132 ± 3 vs. 100 ± 3 mmHg in LSD rats, P < 0.001) (78). Thus dopaminergic stimulation with bromocriptine produced -MSH deficiency during ingestion of the HSD, and this was accompanied by the development of salt-sensitive hypertension. As was true with -MSH-deficient PC2-/- mice, infusion of the peptide at a physiologically relevant rate restored MAP to control values very quickly (78). These results indicate that pharmacologic treatment known to interfere with POMC processing results in -MSH deficiency and that this deficiency is associated with the occurrence of salt-sensitive hypertension. Because other pathways requiring PC2 for prohormone processing were not likely to be affected by bromocriptine treatment, this finding strengthens the contention that hypertension in PC2-/- mice is a reflection of impaired POMC processing into -MSH. These observations provide further support for an important role of -MSH in sodium metabolism; deficiency of this peptide results in the development of salt-sensitive hypertension.

The studies described above allow the development of a scheme depicting the major elements of the physiology and pathophysiology of the -MSH system in the regulation of sodium metabolism (Fig. 5). Ingestion of a diet high in sodium content generates a signal that ultimately reaches the pituitary. The nature of this signal is at present obscure. It could arise from sensory afferents in cardiopulmonary and arterial baroreceptor regions responding to the increase in blood volume, which results from sodium retention in the early period of exposure to the new dietary intake. An alteration in geometric relationships of structures surrounding the third cerebral ventricle has also been suggested to serve as a mediator of changes in sodium intake (63), as has an increase in sodium concentration in the cerebrospinal fluid (CSF) (82). This increase is then transmitted to the pituitary NIL via a series of intermediate steps. We showed that the opioid receptor antagonist naloxone blocked the postnephrectomy natriuresis when administered directly into the CSF (68); insofar as pathways regulating POMC processing and -MSH secretion in response to a high dietary sodium intake are the same as those mediating natriuresis after AUN, this observation indicates an opioidergic step in the neural pathway to the NIL. As discussed above, dopaminergic regulation of NIL function is established, and the data just presented indicate that manipulation of dopaminergic activity profoundly influences NIL -MSH content, plasma -MSH concentration, and MAP. Release of tonic dopaminergic suppression leads to increases in POMC and its processing enzymes PC1 and PC2 and an increase in NIL -MSH content. The NIL is viewed as the source of circulating -MSH (4, 44, 111), and plasma concentration of the peptide then rises. -MSH interacts with MC3-R in the kidney to stimulate natriuresis without an increase in GFR, indicating an inhibition of tubular reabsorption. Mice deficient in this receptor do not increase U_NaV during -MSH infusion, whereas -MSH-deficient PC2-/- mice show the expected natriuretic response to infusion of the peptide (88). The inhibition of sodium reabsorption by -MSH occurs via an interaction with some aspect of renal nerve function, because natriuresis does not occur in denervated kidneys (14). The high sodium intake must also activate other natriuretic pathways such as the ANP system and suppress antinatriuretic pathways like the renin-angiotensin system and aldosterone, all of which actions work in concert with -MSH to increase U_NaV to match the new dietary intake and thereby restore sodium balance. The natriuresis would contribute to the maintenance of normal blood pressure, although other actions of -MSH must also be involved. The lowering of MAP with -MSH infusion in -MSH-deficient PC2-/- mice with hypertension seems too rapid to be due solely to natriuresis, and the even more rapid reduction in MAP that occurs after intracerebroventricular administration of the peptide argues strongly for a central site of action. MC3-R are expressed in abundance in hypothalamus (1, 104), and -MSH does not lower MAP in hypertensive Mc3r-deficient mice (88). This would suggest that, in addition to stimulating NIL synthesis and secretion of the peptide, the HSD must also lead to central interaction of -MSH with MC3-R, probably in the hypothalamus, to maintain normal blood pressure. Much evidence links salt sensitivity of blood pressure to heightened sympathetic nervous system outflow (112), and it may be that -MSH, acting through MC3-R, serves as a tonic brake on sympathetic drive in the setting of excess dietary sodium intake. Failure of the synthesis and secretion of the peptide to increase during ingestion of the HSD, as in PC2-/- mice and bromocriptine-treated rats, or absent cell signaling as occurs in Mc3r-/- mice, releases this brake and allows sympathetic outflow to increase, resulting in salt-sensitive hypertension. If this increased outflow included increased efferent renal sympathetic nerve activity, sodium reabsorption would be stimulated (25). Such a scheme is of course highly speculative and will require extensive work to confirm. But it offers the opportunity to formulate discrete hypotheses that can be tested experimentally, extending our understanding of this previously unrecognized but functionally important hormonal system. Finally, it is worth pointing out the biphasic nature of -MSH injections or infusions identified by others (44, 73): in picomolar amounts the peptide is natriuretic and is antihypertensive in hypertensive rodents with -MSH deficiency, whereas in nanomolar-to-micromolar amounts natriuresis is lost and blood pressure and heart rate increase, reflecting stimulation of sympathetic outflow probably from central activation of the FMRFamide gated sodium channel.

View larger version (20K): [in this window] [in a new window]   Fig. 5. Schematic diagram to indicate the role of -MSH in the adjustments to an HSD. Through as yet unknown pathways, the HSD sends a signal to the pituitary intermediate lobe to increase the mRNA abundance of POMC and its processing enzymes PC1 and PC2. This leads to increased secretion of -MSH and a rise in its concentration in plasma. The peptide then acts through its receptor MC3-R on the kidneys to increase sodium excretion (UNaV) and on the brain, possibly to inhibit sympathetic nervous system outflow. Deficiency of the peptide, or disrupted signaling through melanocortin receptors (MC3-R), results in salt-sensitive hypertension. See text for details.

	THE -MSH SYSTEM IN HUMANS

TOP ABSTRACT POMC METABOLISM AND PROCESSING THE MELANOCORTINS AND THEIR... CARDIOVASCULAR ACTIONS OF... {gamma}-MSH AND NATRIURESIS {gamma}-MSH AND THE... {gamma}-MSH AND SODIUM... {gamma}-MSH AND SALT-SENSITIVE... THE {gamma}-MSH SYSTEM IN... GRANTS REFERENCES

 
The work described above has indicated that -MSH derived from NIL POMC is importantly involved in the normal adjustments to a high sodium intake in rodents. In humans, no discrete intermediate lobe can be demonstrated anatomically, in distinction to rodents. However, cells can be identified in the human pituitary with histochemical and immunocytochemical characteristics of melanotrophs (2, 36, 44, 93, 128), and -MSH-like immunoreactivity has been identified, although not fully characterized, in human plasma (30, 31, 43, 118). Components of the -MSH system, including POMC, PC1, PC2, and various MC-Rs, are found in many human tissues (15, 127), and ₂-MSH has been extracted from human heart (31). The functional significance of these observations is not clear. Increases in plasma ₂-MSH concentration have been observed after graded exercise in young healthy subjects (118) and in patients with moderate-to-severe congestive heart failure (30). High-affinity binding of Lys-₃-MSH to rat adrenal cortex has been reported (96), and Griffing et al. (43) observed that plasma -MSH concentration was significantly elevated in patients with idiopathic hyperaldosteronism and aldosterone-producing adenomas compared with patients with essential hypertension or normal subjects. Moreover, they found that Lys-₃-MSH stimulated aldosterone secretion in a dose-dependent manner from dispersed cortical cells isolated from adrenal adenomas removed from two patients (43). These observations opened the possibility that Lys-₃-MSH could be a mediator of hyperaldosteronism-related hypertension, following up on the case study reported by Franco-Saenz and colleagues (36). However, the significance of these findings must be questioned after the cloning and characterization of the melanocortin receptors has revealed that MC2-R, expressed predominately in the adrenal cortex, has affinity only for ACTH, with no appreciable affinity for the MSH peptides (108). Messenger RNA for MC5-R has also been detected in low abundance in human adrenal gland (15), so it is possible that signaling by MSH peptides could occur via this receptor. This also seems unlikely given that the affinity of this receptor for -MSH peptides is very low (109).

Mutations in genes of the melanocortin system have been observed in humans but to date have not shed light on the role of this system in cardiovascular homeostasis. Two children with genetic POMC deficiency have been described (60). They had adrenal insufficiency because of lack of ACTH, red hair pigmentation because of -MSH deficiency, and obesity. With glucocorticoid replacement, they developed normally but remained obese. Cardiovascular function in these patients was reported as normal (61). The phenotype of these children is duplicated in Pomc null mice (129). Mutations in melanocortin receptors have also been identified as causes of obesity. Screening of an obese population detected mutations in MC4-R in 4% of the subjects, suggesting that such mutations might be relatively common genetic causes of obesity (117). Severity of the obesity correlated with the in vitro activity of the mutant MC4-Rs (34) and binge eating has been identified as a phenotype of MC4-R gene mutations (9). As mentioned earlier, targeted disruption of mouse Mc4r results in an obese phenotype with normal blood pressure. Mutations in MC3-R have also been identified, but attempts to link them to obesity have been unsuccessful (64, 66, 106). There is virtually no information about this system, particularly -MSH, in cardiovascular homeostasis in humans. It is to be hoped that the data summarized in this review will stimulate interest in the study of this area.

	GRANTS

TOP ABSTRACT POMC METABOLISM AND PROCESSING THE MELANOCORTINS AND THEIR... CARDIOVASCULAR ACTIONS OF... {gamma}-MSH AND NATRIURESIS {gamma}-MSH AND THE... {gamma}-MSH AND SODIUM... {gamma}-MSH AND SALT-SENSITIVE... THE {gamma}-MSH SYSTEM IN... GRANTS REFERENCES

 
This work was supported by RO1-HL-68871 from the National Heart, Lung, and Blood Institute.

	ACKNOWLEDGMENTS

 
The author acknowledges the many contributions of the research fellows and collaborators who have advanced our understanding of the -MSH system over the years. I particularly thank Eckehart Wiedemann, MD, whose detailed knowledge of POMC and its peptides got this project started and kept it going in the right direction; Shan-Yan Lin, MD, whose scientific insight and experimental prowess led to much of the data, which allowed it to go forward; and Xi-Ping Ni, MD, whose resourcefulness and technical skill have contributed greatly to our recent findings.

	FOOTNOTES

 

Address for reprint requests and other correspondence: M. H. Humphreys, Box 1341, UCSF, San Francisco, CA 94143-1341 (E-mail: mhhsfgh{at}itsa.ucsf.edu).

	REFERENCES

TOP ABSTRACT POMC METABOLISM AND PROCESSING THE MELANOCORTINS AND THEIR... CARDIOVASCULAR ACTIONS OF... {gamma}-MSH AND NATRIURESIS {gamma}-MSH AND THE... {gamma}-MSH AND SODIUM... {gamma}-MSH AND SALT-SENSITIVE... THE {gamma}-MSH SYSTEM IN... GRANTS REFERENCES

 

1. Adan RA and Gispen WH. Brain melanocortin receptors: from cloning to function. Peptides 18: 1279-1287, 1997.[CrossRef][Web of Science][Medline]
2. Ali-Rachedi A, Ferri GL, Varndell IM, Van Noorden S, Schot LPC, Ling N, Bloom SR, and Polak JM. Immunocytochemical evidence for the presence of -MSH-like immunoreactivity in pituitary corticotrophs and ACTH-producing tumors. Neuroendocrinology 37: 427-433, 1983.[Web of Science][Medline]
3. Allen RG, Peng B, Pellegrino MJ, Miller ED, Grandy DK, Lundblad JR, Washburn CL, and Pintar JE. Altered processing of pro-orphanin FQ/nociceptin and pro-opiomelanocortin-derived peptides in the brains of mice expressing defective prohormone convertase 2. J Neurosci 21: 5864-5870, 2001.[Abstract/Free Full Text]
4. Autelitano DJ, Lundblad JR, Blum M, and Roberts JL. Hormonal regulation of POMC gene expression. Annu Rev Physiol 51: 715-726, 1989.[CrossRef][Web of Science][Medline]
5. Ayus JC and Humphreys MH. Hemodynamic and renal functional changes after unilateral nephrectomy in the dog: role of carotid sinus baroreceptors. Am J Physiol Renal Fluid Electrolyte Physiol 242: F181-F189, 1982.[Abstract/Free Full Text]
6. Benjannet S, Savaria D, Chretien M, and Seidah NB. 7B2 is a specific intracellular binding protein of the prohormone convertase PC2. J Neurochem 64: 2303-2311, 1995.[Web of Science][Medline]
7. Berman Y, Mzhavia N, Polonskaia A, Furuta M, Steiner DF, Pintar JE, and Devi LA. Defective prodynorphin processing in mice lacking prohormone convertase PC2. J Neurochem 75: 1763-1770, 2000.[CrossRef][Web of Science][Medline]
8. Braas KM, Hendley ED, and May V. Anterior pituitary proopiomelanocortin expression is decreased in hypertensive rat strains. Endocrinology 134: 196-205, 1994.[Abstract/Free Full Text]
9. Branson R, Potoczna N, Kral JG, Lentes KU, Hoehe MR, and Horber FF. Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N Engl J Med 348: 1096-1103, 2003.[Abstract/Free Full Text]
10. Butler AA, Kesterson RA, Khong K, Cullen MJ, Pelleymounter MA, Dekoning J, Baetscher J, and Cone RD. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141: 3518-3521, 2000.[Abstract/Free Full Text]
11. Callahan MF, Cunningham JT, Kirby RF, Johnson AK, and Gruber KA. Role of the anteroventral third ventricle (AV3V) region of the rat brain in the pressor response to gamma 2-melanocyte stimulating hormone (gamma 2-MSH). Brain Res 444: 177-180, 1988.[CrossRef][Web of Science][Medline]
12. Chandramohan G, Ni XP, Kalinyak JE, and Humphreys MH. Dietary sodium modulates mRNA abundance of enzymes involved in pituitary processing of proopiomelanocortin. Pituitary 4: 231-237, 2001.[CrossRef][Medline]
13. Chen W, Kelly MA, Opitz-Araya X, Thomas RE, Low MJ, and Cone RD. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 91: 789-798, 1997.[CrossRef][Web of Science][Medline]
14. Chen XW, Ying WZ, Valentin JP, Ling KT, Lin SY, Wiedemann E, and Humphreys MH. Mechanism of the natriuretic action of -melanocyte-stimulating hormone. Am J Physiol Regul Integr Comp Physiol 272: R1946-R1953, 1997.[Abstract/Free Full Text]
15. Chhajlani V. Distribution of cDNA for melanocortin receptor subtypes in human tissues. Biochem Mol Biol Int 38: 73-80, 1996.[Web of Science][Medline]
16. Chiao H, Foster S, Thomas R, Lipton J, and Star RA. -Melanocyte stimulating hormone reduces endotoxin-induced liver inflammation. J Clin Invest 97: 2038-2044, 1996.[Web of Science][Medline]
17. Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, and Star RA. -Melanocyte stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 99: 1165-1172, 1997.[Web of Science][Medline]
18. Chiao H, Kohda Y, McLeroy P, Craig L, Linas S, and Star RA. -Melanocyte stimulating hormone inhibits renal injury in the absence of neutrophils. Kidney Int 54: 765-774, 1998.[CrossRef][Web of Science][Medline]
19. Clark AJL and Weber A. Molecular insights into inherited ACTH resistance syndromes. Trends Endocrinol Metab 5: 209-214, 1994.[Medline]
20. Day R, Schafer MK, Watson SJ, Chretien M, and Seidah N. Distribution and regulation of the prohormone convertases PC1 and PC2 in the rat pituitary. Mol Endocrinol 6: 485-497, 1992.[Abstract/Free Full Text]
21. DeBold CR, Nicholson WE, and Orth DN. Immunoreactive proopiomelanocortin (POMC) peptides and POMC-like messenger ribonucleic acid are present in many rat nonpituitary tissues. Endocrinology 122: 2648-2657, 1988.[Abstract/Free Full Text]
22. Desarnaud F, Labbe O, Eggerickx D, Vassart G, and Parmentier M. Molecular cloning, functional expression, and pharmacological characterization of a mouse melanocortin receptor gene. Biochem J 299: 367-373, 1994.[Web of Science][Medline]
23. De Wildt DJ, Krugers H, Kasbergen CM, De Lang H, and Versteeg DHG. The hemodynamic effects of ₂-melanocyte stimulating hormone and related melanotropins depend on the arousal potential of the rat. Eur J Pharmacol 233: 157-164, 1993.[CrossRef][Web of Science][Medline]
24. DeWildt DJ, Van Der Ven JC, Van Bergen P, DeLang H, and Versteeg DHG. A hypotensive and bradycardic action of ₂-melanocyte stimulating hormone (₂-MSH) microinjected into the nucleus tractus solitarii of the rat. Naunyn Schmiedebergs Arch Pharmacol 349: 50-56, 1994.[Web of Science][Medline]
25. DiBona GF and Kopp UC. Neural control of renal function. Annu Rev Physiol 77: 75-197, 1997.
26. Diezi J, Michoud-Hausel P, and Nicolas-Buxcel N. Studies on possible mechanisms of early functional compensatory adaptation in the remaining kidney. Yale J Biol Med 51: 265-270, 1978.[Web of Science][Medline]
27. Dirks JH and Wong NLM. Acute functional adaptation to nephron loss. Micropuncture studies. Yale J Biol Med 51: 225-263, 1978.
28. Duchen LW. The effects of ingestion of hypertonic saline on the pituitary gland in the rat. A morphological study of the pars intermedia and posterior lobe. J Endocrinol 25: 162-168, 1962.
29. Dunbar JC and Lu H. Proopiomelanocortin (POMC) products in the central regulation of sympathetic and cardiovascular dynamics: studies on melanocortin and opioid interactions. Peptides 21: 211-217, 2000.[CrossRef][Web of Science][Medline]
30. Edvinsson I, Ekman R, Hedner P, Sjoholm A, and Valdemarsson S. Gamma 2-MSH in congestive heart failure: relation to atrial natriuretic peptide, arginine vasopressin and catecholamines. J Intern Med 227: 183-187, 1990.[Web of Science][Medline]
31. Ekman R, Bjartell A, Lisander B, and Edvinsson L. ₂-MSH immunoreactivity in the human heart. Life Sci 45: 787-792, 1989.[CrossRef][Web of Science][Medline]
32. Elkabes S and Loh YP. Effect of salt loading on proopiomelanocortin (POMC) messenger ribonucleic acid levels, POMC biosynthesis, and secretion of POMC products in the mouse pituitary gland. Endocrinology 123: 1754-1760, 1988.[Abstract/Free Full Text]
33. Englaro W, Rezzonico R, Durand-Clement M, Lallemand D, Ortonne JP, and Ballotti R. Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP induced melanogenesis in B-16 melanoma cells. J Biol Chem 270: 24315-24320, 1995.[Abstract/Free Full Text]
34. Farooqi IS, Keogh JM, Yeo GSM, Lank EJ, Cheetham T, and O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348: 1085-1095, 2003.[Abstract/Free Full Text]
35. Felder RA and Garland DS. POMC biosynthesis in the intermediate lobe of the spontaneously hypertensive rat. Am J Hypertens 2: 618-624, 1989.[Web of Science][Medline]
36. Franco-Saenz R, Mulrow PJ, and Kim K. Idiopathic aldosteronism: a possible disease of the intermediate lobe of the pituitary. JAMA 251: 2555-2558, 1984.[Abstract/Free Full Text]
37. Frankel MB, Aldred PG, and McDougall JG. Sodium status affects GC-B natriuretic receptor mRNA levels, but not GC-A or C receptor mRNA levels in the sheep kidney. Clin Sci (Colch) 86: 517-522, 1994.[Medline]
38. Furuta M, Yano H, Shou A, Rouille A, Holst JJ, Carroll R, Ravazzola M, Orci L, Furuta H, and Steiner DF. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc Natl Acad Sci USA 94: 6646-6651, 1997.[Abstract/Free Full Text]
39. Furuta M, Zhou A, Webb G, Carroll R, Ravazzola M, Orci L, and Steiner DF. Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. J Biol Chem 276: 27197-27202, 2001.[Abstract/Free Full Text]
40. Gaida W, Lang RE, Kraft K, Unger T, and Ganten D. Altered neuropeptide concentrations in spontaneously hypertensive rats: cause or consequence? Clin Sci (Colch) 68: 35-43, 1985.[Medline]
41. Gantz I and Fong TM. The melanocortin system. Am J Physiol Endocrinol Metab 284: E468-E474, 2003.[Abstract/Free Full Text]
42. Gantz I, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, DelValle J, and Yamada T. Molecular cloning of a novel melanocortin receptor. J Biol Chem 268: 8246-8250, 1993.[Abstract/Free Full Text]
43. Griffing GT, Berelowits B, Hudson M, Salzman R, Manson JE, Aurrechia S, Melby JC, Pedersen RC, and Brownie AC. Plasma immunoreactive gamma melanotropin in patients with idiopathic hyperaldosteronism, aldosterone-producing adenomas, and essential hypertension. J Clin Invest 76: 163-169, 1985.[Web of Science][Medline]
44. Gruber KA and Callahan MF. ACTH-(4-10) through -MSH: evidence for a new class of central autonomic nervous system-regulating peptides. Am J Physiol Regul Integr Comp Physiol 257: R681-R694, 1989.[Abstract/Free Full Text]
45. Gruber KA and Eskridge SL. Central vasopressin system mediation of acute pressor effect of -MSH. Am J Physiol Endocrinol Metab 251: E134-E137, 1986.[Abstract/Free Full Text]
46. Hao J and Rabkin SW. Differences in pituitary expression of proopiomelanocortin in Dahl salt-resistant and salt-sensitive rats on a high salt diet. Can J Physiol Pharmacol 74: 657-662, 1996.[CrossRef][Web of Science][Medline]
47. Hill C and Dunbar JC. The effects of acute and chronic alpha melanocyte stimulating hormone (MSH) on cardiovascular dynamics in conscious rats. Peptides 23: 1625-1630, 2002.[CrossRef][Web of Science][Medline]
48. Howe A and Thody AJ. The effect of ingestion of hypertonic saline on the melanocyte-stimulating hormone content and histology of the pars intermedia of the rat pituitary gland. J Endocrinol 46: 201-208, 1970.[Abstract/Free Full Text]
49. Hradec J and Horky K. Natriuretic and kaliuretic effect of melanocyte stimulating hormones in hamster. Endocr J 13: 145-152, 1979.
50. Hruby VJ, Lu D, Sharma SD, Castrucci A, Kesterson RA, Al-Obeidi FA, Hadley ME, and Cone RD. Cyclic lactam -melanotropin analogues of Ac-Nle⁴-cyclo[Asp⁵,D-Phe⁷,Lys¹⁰] -melanocyte stimulating hormone (4-10)-NH₂ with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J Med Chem 38: 3454-3461, 1995.[CrossRef][Web of Science][Medline]
51. Huang BS and Leenen FHH. Brain amiloride-sensitive Phe-Met-Arg-Phe-NH₂-gated Na⁺ channels and Na⁺-induced synmpathoexcitation and hypertension. Hypertension 39: 557-561, 2002.[Abstract/Free Full Text]
52. Humphreys MH, Al-Bander H, Eneas JF, and Schambelan M. Factors determining electrolyte excretion and renin secretion after closure of an arteriovenous fistula in the dog. J Lab Clin Med 98: 89-98, 1981.[Web of Science][Medline]
53. Humphreys MH and Ayus JC. Role of hemodynamic changes in the increased cation excretion after acute unilateral nephrectomy in the anesthetized dog. J Clin Invest 61: 590-596, 1978.[Web of Science][Medline]
54. Humphreys MH, Ayus JC, and Stanton CJ. Prevention by vagotomy or atropine administration of the hemodynamic changes occurring after acute unilateral nephrectomy in the dog. Circ Res 46: 575-580, 1980.[Free Full Text]
54. Humphreys MH and Lin SY. Peptide hormones and the regulation of sodium excretion. Hypertension 11: 397-410, 1988.[Free Full Text]
55. Humphreys MH, Lin SY, and Wiedemann E. Renal nerves and the natriuresis following unilateral renal exclusion in the rat. Kidney Int 39: 63-70, 1991.[Web of Science][Medline]
56. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, and Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88: 131-141, 1997.[CrossRef][Web of Science][Medline]
57. Kivipelto L, Majane EA, Yang HYT, and Panula P. Immunohistochemical distribution and partial characterization of FLFQPQRFamide-like peptides in the central nervous system of rats. J Comp Neurol 286: 269-287, 1989.[CrossRef][Web of Science][Medline]
58. Kojima I, Kojima K, and Rasmussen H. Role of calcium and cAMP in the action of adrenocorticotropin in the action of adrenocorticotropin on aldosterone secretion. J Biol Chem 260: 4248-4256, 1985.[Abstract/Free Full Text]
59. Konda Y, Gantz I, DelValle J, Shimoto Y, Miwa H, and Yamada T. Interaction of dual intracellular signaling pathways activated by the melanocortin-3 receptor. J Biol Chem 269: 13162-13166, 1994.[Abstract/Free Full Text]
60. Krude H, Biebermann H, Luck W, Horn R, Brabant G, and Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19: 155-157, 1998.[CrossRef][Web of Science][Medline]
61. Krude H and Bruters A. Implications of proopiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome. Trends Endocrinol Metab 11: 15-22, 2000.[CrossRef][Web of Science][Medline]
62. Laurent V, Kimble A, Peng B, Zhu P, Pintar JE, Steiner DF, and Lindberg I. Mortality in 7B2 null mice can be rescued by adrenalectomy: involvement of dopamine in ACTH hypersecretion. Proc Natl Acad Sci USA 99: 3087-3092, 2002.[Abstract/Free Full Text]
63. Lee JY, Tobian L, Hanlon S, Hammer R, Johnson MA, and Iwai J. How is the signal transmitted in NaCl-induced hypertension? Hypertension 13: 668-675, 1989.[Abstract/Free Full Text]
64. Lee YS, Poh LK, and Loke KY. A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. J Clin Endocrinol Metab 87: 1423-1426, 2002.[Abstract/Free Full Text]
65. Li SJ, Varga K, Archer P, Hruby VJ, Sharma SD, Kesterson RA, Cone RD, and Kunos G. Melanocortin antagonists define two distinct pathways of cardiovascular control by - and -melanocyte stimulating hormones. J Neurosci 16: 5182-5188, 1996.[Abstract/Free Full Text]
66. Li WD, Joo EJ, Furlong EB, Galvin M, Abel K, Bell CJ, and Price RA. Melanocortin 3 receptor (MC3R) gene variants in extremely obese women. Int J Obes Relat Metab Disord 24: 206-210, 2000.[CrossRef][Web of Science][Medline]
67. Lin SY, Chaves C, Wiedemann E, and Humphreys MH. A -MSH like peptide causes reflex natriuresis after acute unilateral nephrectomy. Hypertension 10: 619-627, 1987.[Abstract/Free Full Text]
68. Lin SY and Humphreys MH. Centrally administered naloxone blocks reflex natriuresis after acute unilateral nephrectomy. Am J Physiol Renal Fluid Electrolyte Physiol 249: F390-F395, 1985.[Abstract/Free Full Text]
69. Lin SY, Wiedemann E, Deschepper CF, Alper RN, and Humphreys MH. Prevention of reflex natriuresis after acute unilateral nephrectomy by neonatal administration of monosodium glutamate. Am J Physiol Renal Fluid Electrolyte Physiol 252: F276-F282, 1987.[Abstract/Free Full Text]
70. Lin SY, Wiedemann E, and Humphreys MH. Role of the pituitary in the reflex natriuresis after acute unilateral nephrectomy. Am J Physiol Renal Fluid Electrolyte Physiol 249: F390-F395, 1985.[Abstract/Free Full Text]
71. Lingueglia E, Champigny G, Lazdunski M, and Barbry P. Cloning of the amiloride-sensitive FMRFamide peptide-gated sodium channel. Nature 378: 730-733, 1995.[CrossRef][Medline]
72. Lu H, Buison A, Jen KLC, and Dunbar JC. Leptin resistance in obesity is characterized by decreased sensitivity to proopiomelanocortin products. Peptides 21: 1479-1485, 2000.[CrossRef][Web of Science][Medline]
73. Lymangrover JR, Buckalew VM, Harris J, Klein MC, and Gruber KA. Gamma-2 MSH is natriuretic in the rat. Endocrinology 116: 1227-1229, 1984.
74. Matsumura K, Tsuchihashi T, Abe I, and Iida M. Central -melanocyte-stimulating hormone acts at melanocortin-4 receptor to activate sympathetic nervous system in conscious rabbits. Brain Res 948: 143-148, 2002.
75. Matsumura K, Tsuchihashi T, Fujii K, and Iida M. Neural regulation of blood pressure by leptin and the related peptides. Regul Pept 114: 79-86, 2003.[CrossRef][Web of Science][Medline]
76. Mayan H, Ling KT, Kalinyak JE, Sharma A, Wiedemann E, and Humphreys MH. Modulation by dietary salt intake of pituitary proopiomelanocortin (POMC) messenger RNA (mRNA) abundance in normotensive and hypertensive rats (Abstract). Hypertension 22: 417, 1993.
77. Mayan H, Ling KT, Lee EY, Wiedemann E, Kalinyak JE, and Humphreys MH. Dietary sodium intake modulates pituitary proopiomelanocortin messenger RNA abundance. Hypertension 28: 244-249, 1996.[Abstract/Free Full Text]
78. Mayan H, Ni XP, Almog S, and Humphreys MH. Suppression of -melanocyte stimulating hormone secretion is accompanied by salt-sensitive hypertension in the rat. Hypertension 42: 962-967, 2003.[Abstract/Free Full Text]
79. Mountjoy KG, Kong PL, Taylor JA, Willard DA, and Wilkison WO. Melanocortin receptor-mediated mobilization of intracellular free calcium in HEK293 cells. Physiol Genomics 5: 11-19, 2001.[Abstract/Free Full Text]
80. Mountjoy KG, Robbins LS, Mortrud MT, and Cone RD. The cloning of a family of genes that encode the melanocortin receptors. Science 257: 1248-1251, 1992.[Abstract/Free Full Text]
81. Mues G, Fuchs I, Wei ET, Weber E, Evans CJ, Barchas JD, and Chang JK. Blood pressure elevation in rats by peripheral administration of Tyr-Gly-Gly-Phe-Met-Arg-Phe and the invertebrate neuropeptide, Phe-Met-Arg-Phe-NH₂. Life Sci 31: 2555-2561, 1982.[CrossRef][Web of Science][Medline]
82. Nakamura K and Cowley AW Jr. Sequential changes of cerebrospinal fluid sodium during the development of hypertension in Dahl rats. Hypertension 13: 243-249, 1989.[Abstract/Free Full Text]
83. Nakanishi S, Inoue A, Kita T, Nakamura M, Chang ACY, Cohen SN, and Numa S. Nucleotide sequence of cloned cDNA for bovine corticotropin- lipotropin precursor. Nature 278: 423-427, 1979.[CrossRef][Medline]
84. Nemeroff CB, Grant LD, Bissette G, Ervin GN, Havell LE, and Prange AJ Jr. Growth, endocrinological, and behavioral deficits after monosodium L-glumatate in the rat: possible involvement of arcuate dopamine neuron damage. Psychoneuroendocrinology 2: 179-196, 1977.[CrossRef][Web of Science][Medline]
85. Ni XP, Bhargava A, Pearce D, and Humphreys MH. Dietary sodium intake modulates renal expression of melanocortin 3 receptor (MC3-R) mRNA and protein abundance in the rat (Abstract). J Am Soc Nephrol 13: 81A, 2002.
86. Ni XP, Butler AA, Cone RD, and Humphreys MH. Cardiovascular actions of -melanocyte stimulating hormone (-MSH): role of the melanocortin 3 receptor (MC3-R) (Abstract). J Am Soc Nephrol 14: 141A, 2003.
87. Ni XP, Kesterson RA, Sharma SD, Hruby VJ, Cone RD, Wiedemann E, and Humphreys MH. Prevention of reflex natriuresis after acute unilateral nephrectomy by melanocortin receptor antagonists. Am J Physiol Regul Integr Comp Physiol 274: R931-R938, 1998.[Abstract/Free Full Text]
88. Ni XP, Pearce D, Butler AA, Cone RD, and Humphreys MH. Genetic disruption of -melanocyte-stimulating hormone signaling leads to salt-sensitive hypertension in the mouse. J Clin Invest 111: 1251-1258, 2003.[CrossRef][Web of Science][Medline]
89. Nijsen MJMA, de Ruiter GJW, Kasbergen CM, Hoogerhout P, and de Wildt DJ. Relevance of the C-terminal arg-phe sequence in ₂-melanocyte-stimulating hormone (₂-MSH) for inducing cardiovascular effects in conscious rats. Br J Pharmacol 131: 1468-1474, 2000.[CrossRef][Web of Science][Medline]
90. Nishimura M, Ohtsuka K, Takahashi H, and Yoshimura M. Role of FMRFamide-activated brain sodium channel in salt-sensitive hypertension. Hypertension 35: 443-450, 2000.[Abstract/Free Full Text]
91. Oosterom J, Nijenhuis WA, Schaaper WM, Slootstra J, Meloen RH, Gispen WH, Burbach JP, and Adan RA. Conformation of the core sequence in melanocortin peptides directs selectivity for the melanocortin MC3 and MC4 receptors. J Biol Chem 274: 16853-16860, 1999.[Abstract/Free Full Text]
92. Orias R and McCann SM. Natriuresis induced by alpha and beta melanocyte stimulating hormone (MSH) in rats. Endocrinology 90: 700-706, 1972.[Abstract/Free Full Text]
93. Osamura RY, Watanabe K, Tanaka I, Nakai Y, and Imura H. Comparative immunohistochemical studies of -melanocyte stimulating hormone (-MSH) and adrenocorticotrophic hormone (ACTH) in the bovine and human pituitaries. Acta Endocrinol 96: 458-463, 1981.[Medline]
94. Oyarce AM, Hand TA, Mains RE, and Eipper BE. Dopaminergic regulation of secretory granule-associated proteins in rat intermediate pituitary. J Neurochem 67: 229-241, 1996.[Web of Science][Medline]
95. Pavia JM, Schioth HB, and Morris MJ. Role of MC4 receptors in the depressor and bradycardic effects of -MSH in the nucleus tractus solitarii of the rat. Neuroreport 14: 703-707, 2003.[CrossRef][Web of Science][Medline]
96. Pedersen RC and Brownie AC. Lys-₃-Melanotropin binds with high affinity to the rat adrenal cortex. Endocrinology 112: 1279-1287, 1983.[Abstract/Free Full Text]
97. Peters G. Compensatory adaptation of renal functions in the anesthetized rat. Am J Physiol 205: 1042-1048, 1963.[Abstract/Free Full Text]
98. Price DA and Greenberg MJ. Structure of a molluscan cardioexcitatory neuropeptide. Science 197: 670-671, 1977.[Abstract/Free Full Text]
99. Pritchard LE, Turnbull AV, and White A. Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesity. J Endocrinol 172: 411-421, 2002.[Abstract]
100. Qiu C, Valentin JP, Chen XW, Wiedemann E, and Humphreys MH. Acute unilateral nephrectomy elicits a specific increase in plasma of peptides derived from the N-terminal region of proopiomelanocortin. J Am Soc Nephrol 3: 1105-1112, 1992.[Abstract]
101. Ramaekers D, Beckers F, Demeulemeester H, Bert C, Denef C, and Aubert AE. Effects of melanocortins on cardiovascular regulation in rats. Clin Exp Pharmacol Physiol 29: 549-558, 2002.[CrossRef][Web of Science][Medline]
102. Rapp JP and Dahl LK. Anatomical and protein electrophoretic observations on pituitary cleft colloid in rats genetically susceptible or resistant to salt hypertension. Lab Invest 30: 417-426, 1974.[Web of Science]
103. Ribstein J and Humphreys MH. Renal nerves and cation excretion after acute reduction in functioning renal mass in the rat. Am J Physiol Renal Fluid Electrolyte Physiol 246: F260-F266, 1984.[Abstract/Free Full Text]
104. Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, and Cone RD. Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 90: 8856-8860, 1993.[Abstract/Free Full Text]
105. Roumy M and Zajac JM. Neuropeptide FF, pain and analgesia. Eur J Pharmacol 345: 1-11, 1998.[CrossRef][Web of Science][Medline]
106. Schalin-Jantti C, Valli-Jaakola K, Oksanen L, Martelin E, Laitinen K, Krusius T, Mustajoki P, Heikinheimo M, and Kontula K. Melanocortin-3-receptor gene variants in morbid obesity. Int J Obes 27: 70-74, 2003.[CrossRef][Web of Science][Medline]
107. Schioth HB. The physiological role of melanocortin receptors. Vitam Horm 63: 195-232, 2001.[Web of Science][Medline]
108. Schioth HB, Chhajlani V, Muceniece R, Lkusa V, and Wikberg JE. Major pharmacological distinction of the ACTH receptor from other melanocortin receptors. Life Sci 59: 797-801, 1996.[CrossRef][Web of Science][Medline]
109. Schioth HB, Muceniece R, Wikberg JES, and Chhajlani V. Characterization of melanocortin receptor subtypes by radioligand binding analysis. Eur J Pharmacol 288: 311-317, 1995.[CrossRef][Web of Science][Medline]
110. Schioth HB, Phillips S, Rudzish R, Birch-Machin M, Jackson I, Wikberg JES, and Rees JL. Loss of function mutations of the human melanocortin 1 receptor are common and are associated with red hair. Biochem Biophys Res Commun 260: 488-491, 1999.[CrossRef][Web of Science][Medline]
111. Smith AI and Funder JW. Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. Endocr Rev 9: 159-179, 1988.[Abstract/Free Full Text]
112. Strazzullo P, Barbato A, Vuotto P, and Galletti F. Relationship between salt sensitivity of blood pressure and sympathetic nervous system activity: a short review of evidence. Clin Exp Hypertens 23: 25-33, 2001.[CrossRef][Web of Science][Medline]
113. Sun JZ, Chen SH, Majid-Hasan E, Oparil S, and Chen YF. Dietary salt supplementation selectively downregulates NPR-C receptor expression in kidney independently of ANP. Am J Physiol Renal Physiol 282: F220-F227, 2002.[Abstract/Free Full Text]
114. Sun XY, Feng QP, Gong QL, Edvinsson L, and Hedner T. Cardiovascular and renal effects of gamma-MSH in spontaneously hypertensive and normotensive Wistar Kyoto rats. Am J Physiol Regul Integr Comp Physiol 262: R77-R84, 1992.[Abstract/Free Full Text]
115. Thiemermann C, Al-Damluji S, Hecker M, and Vane JR. FMRF-amide and L-Arg-L-Phe increase blood pressure and heart rate in the anesthetized rat by central stimulation of the sympathetic nervous system. Biochem Biophys Res Commun 175: 318-324, 1991.[CrossRef][Web of Science][Medline]
116. Tsigo C, Arai K, Hung W, and Chrousos GP. Hereditary isolated glucocorticoid deficiency is associated with abnormalities of the adrenocorticotropin receptor gene. J Clin Invest 92: 2458-2461, 1993.[Web of Science][Medline]
117. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, and Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106: 253-262, 2000.[Web of Science][Medline]
118. Valdemarsson S, Andersson D, Bengtsson A, Bogren M, Edvinsson L, and Ekman R. Gamma 2-MSH increases during graded exercise in healthy subjects: comparison with plasma catecholamines, neuropeptides, aldosterone and renin activity. Clin Physiol 10: 321-327, 1990.[Web of Science][Medline]
119. Van Bergen P, De Winter TYCE, De Wildt DJ, and Versteeg DHG. Influence of blockade of ₁-adrenoceptors, ₁-adrenoceptors, and vasopressin V_1A receptors on the cardiovascular effects of ₂-melanocyte-stimulating hormone (₂-MSH). Naunyn Schmiedebergs Arch Pharmacol 355: 720-726, 1997.[CrossRef][Web of Science][Medline]
120. Van Bergen P, Janssen PML, Hoogerhout P, De Wildt DJ, and Versteeg DHG. Cardiovascular effects of -MSH/ACTH-like peptides: structure-activity relationship. Eur J Pharmacol 294: 795-803, 1995.[CrossRef][Web of Science][Medline]
121. Van Bergen P, Kleijne JA, De Wildt DJ, and Versteeg DHG. Different cardiovascular profiles of three melanocortins in conscious rats; evidence for antagonism between ₂-MSH and ACTH-(1-24). Br J Pharmacol 120: 1561-1567, 1997.[CrossRef][Web of Science][Medline]
122. Van Bergen P, Van der Vaart JGM, Kasbergen CM, Versteeg DHG, and De Wildt DJ. Structure-activity analysis for the effects of -MSH/ACTH-like peptides on cerebral hemodynamics in rats. Eur J Pharmacol 318: 357-368, 1996.[CrossRef][Web of Science][Medline]
123. Versteeg DHG, Van Bergen P, Adan RAH, and De Wildt DJ. Melanocortins and cardiovascular regulation. Eur J Pharmacol 360: 1-14, 1998.[CrossRef][Web of Science][Medline]
124. Wardlaw SL. Obesity as a neuroendocrine disease: lessons to be learned from proopiomelanocortin and melanocortin receptor mutations in mice and men. J Clin Endocrinol Metab 86: 1442-1446, 2001.[Free Full Text]
125. Weber A, Kapas S, Hinson J, Grant DB, Grossman A, and Clark AJL. Functional characterization of the cloned human ACTH receptor: impaired responsiveness of a mutant receptor in familial glucocorticoid deficiency. Biochem Biophys Res Commun 197: 172-178, 1993.[CrossRef][Web of Science][Medline]
126. Westphal CH, Muller L, Zhou A, Zhu X, Bonner-Weir S, Schambelan M, Steiner DF, Lindberg I, and Leder P. The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease. Cell 96: 689-700, 1999.[CrossRef][Web of Science][Medline]
127. Wikberg JES, Muceniece R, Mandrika I, Prusis P, Lindblom J, Post C, and Skottner A. New aspects on the melanocortins and their receptors. Pharmacol Res 42: 393-420, 2000.[CrossRef][Web of Science][Medline]
128. Wilkes NM, Watkin S, Stewart RD, and Yen SSC. Localization and quantitation of -endorphin in human brain and pituitary. Neuroendocrinology 30: 113-121, 1980.[Web of Science][Medline]
129. Yaswen L, Diehl N, Brennan MB, and Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5: 1066-1070, 1999.[CrossRef][Web of Science][Medline]
130. Yeo GSH, Farooqi IS, Challis BG, Jackson RS, and O'Rahilly S. The role of melanocortin signalling in the control of body weight: evidence from human and murine genetic models. QJM 93: 7-14, 2000.[Abstract/Free Full Text]
131. Ying WZ, Wiedemann E, and Humphreys MH. Captopril treatment restores the responsiveness of spontaneously hypertensive rats (SHR) to the natriuretic action of intrarenal -melanocyte stimulating hormone (-MSH) (Abstract). J Am Soc Nephrol 3: 529, 1992.
132. Zhou A, Bloomquist BT, and Mains RE. The prohormone convertases PC1 and PC2 mediate distinct endoproteolytic cleavages in a strict temporal order during proopiomelanocortin biosynthetic processing. J Biol Chem 268: 1763-1769, 1993.[Abstract/Free Full Text]
133. Zhou A, Webb G, Zhu X, and Steiner DF. Proteolytic processing in the secretory pathway. J Biol Chem 274: 20745-20748, 1999.[Free Full Text]

This article has been cited by other articles:

				J. M. do Carmo, L. S. Tallam, J. V. Roberts, E. L. Brandon, J. Biglane, A. A. da Silva, and J. E. Hall Impact of obesity on renal structure and function in the presence and absence of hypertension: evidence from melanocortin-4 receptor-deficient mice Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2009; 297(3): R803 - R812. [Abstract] [Full Text] [PDF]

				X.-P. Ni, C. van Dijk, D. Pearce, and M. H. Humphreys Evidence for a noradrenergic mechanism causing hypertension and abnormal glucose metabolism in rats with relative deficiency of \#947;-melanocyte-stimulating hormone Exp Physiol, August 1, 2009; 94(8): 867 - 876. [Abstract] [Full Text] [PDF]

				R. A. Khalil Dietary salt and hypertension: new molecular targets add more spice Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R509 - R513. [Full Text] [PDF]

				X.-P. Ni, A. Bhargava, D. Pearce, and M. H. Humphreys Modulation by dietary sodium intake of melanocortin 3 receptor mRNA and protein abundance in the rat kidney Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R560 - R567. [Abstract] [Full Text] [PDF]

				P. Meneton, X. Jeunemaitre, H. E. de Wardener, and G. A. Macgregor Links Between Dietary Salt Intake, Renal Salt Handling, Blood Pressure, and Cardiovascular Diseases Physiol Rev, April 1, 2005; 85(2): 679 - 715. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (24) Citing Articles via Google Scholar Google Scholar Articles by Humphreys, M. H. Search for Related Content PubMed PubMed Citation Articles by Humphreys, M. H.